Thrombopoietin receptor agonists: ten years later
The two thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, were licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then, their use has progressively increased around the world; they are currently used in more than 100 countries. The six largest...
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado: |
Ferrata Storti Foundation
2019-06-01
|
| Series: | Haematologica |
| Acceso en liña: | https://haematologica.org/article/view/8925 |